Delcath Systems Inc (DCTH)

[13moonster]

Failure to effect a reverse stock split will have a material adverse effect on the Company and its capital structure, including its ability to issue any common stock.
We expect to need at least $20.0 million of cash to fund our operations and clinical trials for the remainder of 2018. Even with the net $4.65 million we just received from our follow on offering, it is unclear whether we will be able to continue as a going concern after May 31, 2018. We do not have access to other sources of debt financing and, without the implementation of a reverse stock split or increasing the number of authorized and unissued shares of our common stock, we are unable to raise a significant amount of equity financing.